CRT links up with Pangaea for PAK inhibitor deal
LONDON—Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK, has begun a license agreement with Pangaea Biotech S.L. for the development of p21-activated kinase (PAK) inhibitor drugs for cancer. Pangaea Biotech will handle research and development of the PAK inhibitors, moving the compounds through clinical development, and will make undisclosed upfront and downstream payments to CRT. The two companies will collaborate to complete lead optimization, after which Pangaea will be responsible for preclinical and clinical development.
“This strategic agreement maximizes the capabilities of both parties, with CRT focusing on the earlier stages of development involving specialized medicinal chemistry work, and Pangaea on regulatory preclinical development, early-stage clinical trials and development of biomarkers, where our main abilities and experience lie,” said Pangaea CEO Javier Rivela. “We are excited about this partnership as it marks the beginning of what we expect to be a fruitful long- term collaboration with one of the most important global players in cancer drug development.”